Meningitis Vaccine
About The Study
You are invited to let your child participate in a biomedical research study of an investigational vaccine. The name of the vaccine is MenACYW conjugate vaccine. The investigational vaccine has been designed to protect against invasive meningococcal disease. Infants who are 6 to 7 months of age and toddlers who are 17 to 19 months of age can take part.
Meningococcal disease (hereafter called “the disease”) is a rare but serious illness that can occur at any age. It can present as meningitis (infection of the covering of the brain and spinal cord), blood infection, or pneumonia
Eligibility Criteria
- Aged 6 to 7 months (168 to 224 days) a or 17 to 19 months on the day of the first visit
- The informed consent form has been signed and dated by the parent(s) or other guardian and by an independent witness if required by local regulations
- Subject and parent/guardian are able to attend all scheduled visits and comply with all trial procedures
- For subjects 6 to 7 months of age at enrollment (Group 1 and Group 2), documented history of having received 2 doses of DTaP, Hib, IPV, pneumococcal, hepatitis B (for children who received Pediarix® at 2 and 4 months of age, prior receipt of 3 doses of hepatitis B), and rotavirus (Rotateq®) vaccines.
- For subjects to be enrolled at 17 to 19 months of age (Group 3 and Group 4), documented history of having received all routine pediatric vaccines recommended by ACIP up to the age of enrollment
Contact Us for Unparalleled Clinical Research Solutions
Discover how our expertise and dedication can accelerate your research success